Can Antidepressants Prevent Pegylated Interferon-α/ribavirin-associated Depression in Patients with Chronic Hepatitis C: Meta-analysis of Randomized, Double-blind, Placebo-controlled Trials?

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Nov 9

PMID 24204676

Citations 5

Authors

Xin-Jiang Hou

Jing-Hang Xu

Jun Wang

Yan-Yan Yu

Affiliations

Soon will be listed here.

Abstract

Background: Antidepressants are effective in treating interferon-α/ribavirin (IFN-α/RBV)-associated depression during or after treatment of chronic hepatitis C (CHC). Whether antidepressant prophylaxis is necessary in this population remains under debate.

Methods: Comprehensive searches were performed in Medline, Embase, Cochrane Controlled Trials Register and PubMed. Reference lists were searched manually. The methodology was in accordance with the 2009 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) Statement.

Results: We identified six randomized, double-blind, placebo-controlled trials involving 522 CHC patients treated with pegylated (PEG)-IFN-α plus RBV. The antidepressants used were escitalopram, citalopram, and paroxetine, which are selective serotonin reuptake inhibitors (SSRIs). The rates of depression (17.9% vs. 31.0%, P = 0.0005), and rescue therapy (27.4% vs. 42.7%, P<0.0001) in the SSRI group were significantly lower than those in the placebo group. The rate of sustained virological response (SVR) (56.8% vs. 50.0%, P = 0.60) and drug discontinuation (18.7% vs. 21.1%, P = 0.63) in the SSRI group did not differ significantly to those in the placebo group. In terms of safety, the incidence of muscle and joint pain (40.8% vs. 52.4%, P = 0.03) and respiratory problems (29.3% vs. 40.1%, P = 0.03) were lower, but the incidence of dizziness was significantly higher (22.3% vs. 10.2%, P = 0.001) in the SSRI group.

Conclusion: Prophylactic SSRI antidepressants can significantly reduce the incidence of PEG-IFN-α/RBV-associated depression in patients with CHC, with good safety and tolerability, without reduction of SVR.

Citing Articles

Drug Interactions of Psychiatric and COVID-19 Medications.

Mohebbi N, Talebi A, Moghadamnia M, Nazari Taloki Z, Shakiba A Basic Clin Neurosci. 2020; 11(2):185-200.

PMID: 32855778 PMC: 7368108. DOI: 10.32598/bcn.11.covid19.2500.1.

Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.

Fourrier C, Sampson E, Mills N, Baune B Trials. 2018; 19(1):447.

PMID: 30126458 PMC: 6102899. DOI: 10.1186/s13063-018-2829-7.

Psychiatric Adverse Effects Of Interferon Therapy.

Coman H, Herta D, Nemes B Clujul Med. 2015; 86(4):318-20.

PMID: 26527969 PMC: 4462448.

Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.

Masip M, Tuneu L, Pages N, Torras X, Gallego A, Guardiola J Int J Clin Pharm. 2015; 37(6):1143-51.

PMID: 26267215 DOI: 10.1007/s11096-015-0177-1.

The definition of placebo in the informed consent forms of clinical trials.

Hernandez A, Banos J, Llop C, Farre M PLoS One. 2014; 9(11):e113654.

PMID: 25423149 PMC: 4244087. DOI: 10.1371/journal.pone.0113654.

References

Hauser P, Khosla J, Aurora H, Laurin J, Kling M, Hill J . A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002; 7(9):942-7. DOI: 10.1038/sj.mp.4001119. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Raison C, Broadwell S, Borisov A, Manatunga A, Capuron L, Woolwine B . Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun. 2004; 19(1):23-7. DOI: 10.1016/j.bbi.2004.05.001. View

Gleason O, Yates W . Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics. 1999; 40(6):510-2. DOI: 10.1016/S0033-3182(99)71190-4. View

Shiffman M, Di Bisceglie A, Lindsay K, Morishima C, Wright E, Everson G . Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004; 126(4):1015-23. DOI: 10.1053/j.gastro.2004.01.014. View

Ghany M, Strader D, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4):1335-74. PMC: 7477893. DOI: 10.1002/hep.22759. View

Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. DOI: 10.1016/s0140-6736(01)06102-5. View

Asnis G, De La Garza 2nd R . Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol. 2006; 40(4):322-35. DOI: 10.1097/01.mcg.0000210099.36500.fe. View

Kraus M, Schafer A, Schottker K, Keicher C, Weissbrich B, Hofbauer I . Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2007; 57(4):531-6. DOI: 10.1136/gut.2007.131607. View

10.

Gleason O, Yates W, Isbell M, Philipsen M . An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002; 63(3):194-8. DOI: 10.4088/jcp.v63n0304. View

11.

Lavanchy D . The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1:74-81. DOI: 10.1111/j.1478-3231.2008.01934.x. View

12.

Cacoub P, Ratziu V, Myers R, Ghillani P, Piette J, Moussalli J . Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol. 2002; 36(6):812-8. DOI: 10.1016/s0168-8278(02)00067-3. View

13.

Schramm T, Lawford B, Macdonald G, Cooksley W . Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust. 2000; 173(7):359-61. DOI: 10.5694/j.1326-5377.2000.tb125687.x. View

14.

Davis G, Wong J, McHutchison J, Manns M, Harvey J, Albrecht J . Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003; 38(3):645-52. DOI: 10.1053/jhep.2003.50364. View

15.

Schafer A, Wittchen H, Seufert J, Kraus M . Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int J Methods Psychiatr Res. 2008; 16(4):186-201. PMC: 6878515. DOI: 10.1002/mpr.229. View

16.

Guadagnino V, Trotta M, Carioti J, Caroleo B, Antinori A . Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users?. Dig Liver Dis. 2005; 38(2):119-24. DOI: 10.1016/j.dld.2005.10.008. View

17.

Bernstein D, Kleinman L, Barker C, Revicki D, Green J . Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002; 35(3):704-8. DOI: 10.1053/jhep.2002.31311. View

18.

Kraus M, Schafer A, Al-Taie O, Scheurlen M . Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat. 2005; 12(1):96-100. DOI: 10.1111/j.1365-2893.2005.00554.x. View

19.

Kraus M, Schafer A, Faller H, Csef H, Scheurlen M . Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 2002; 16(6):1091-9. DOI: 10.1046/j.1365-2036.2002.01265.x. View

20.

Maddock C, Landau S, Barry K, Maulayah P, Hotopf M, Cleare A . Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry. 2005; 10(4):332-3. DOI: 10.1038/sj.mp.4001634. View